ReviewMikrochimica acta2022
Prussian blue: from advanced electrocatalyst to nanozymes defeating natural enzyme.
Review in Mikrochimica acta, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Engineered PB-Mn Nanoplatform Alleviates Bone Loss via Modulating Oxidative Stress and Macrophage Phenotypic Switch.ACS omega · 2026Article
- Nanomaterial-Mediated Electrochemical and Optical Biosensors and Their Application in Tumour Marker Detection.Sensors (Basel, Switzerland) · 2025Review
- Prussian blue nanotechnology in the treatment of spinal cord injury: application and challenges.Frontiers in bioengineering and biotechnology · 2024Review
- NGF-releasing Prussian blue nanoparticles for nerve injury repair of lumbar disc herniation.Frontiers in chemistry · 2024Article
- Single Printing Step Prussian Blue Bulk-Modified Transducers for Oxidase-Based Biosensors.Biosensors · 2023Article
- Nanotechnological strategies to increase the oxygen content of the tumor.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The pathway from the advanced electrocatalyst to nanozymes defeating natural enzyme is reviewed. Prussian blue, being the most advantageous electrocatalyst for hydrogen peroxide reduction, is obviously the best candidate for mimicking peroxidase activity. Indeed, catalytically synthesized Prussian blue nanoparticles are characterized by the catalytic rate constants, which are significantly (up to 4 orders of magnitude) higher than for enzyme peroxidase. Displaying in addition the enzymatic specificity in terms of an absence of oxidase-like activity, catalytically synthesized Prussian blue nanoparticles can be referred to as nanozymes. The latter provide the most versatile method for surface covering with the electrocatalyst, allowing to modify non-traditional materials like boron-doped diamond. For stabilization, Prussian blue core can be covered with nickel hexacyanoferrate shell; the resulting core-shell nanozymes still defeat natural enzyme in terms of activity. Discovering the catalytic pathway of nanozymes "artificial peroxidase" action, we have found the novel advantage of nanozymes over the corresponding biological catalysts: their dramatically (100 times) improved bimolecular rate constants.
Indexed as
Identifiers
35879483What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.